Manufacture

Protein aggregation is difficult to control and predict. Could bedside filtration have a role to play?

Some say lyophilization has changed little in over 70 years, but a new consortium hopes to help change that.

Geert Cauwenbergh believes that RNAi could be the therapeutic of the future.

Cybersecurity is an aspect of business infrastructure that needs to be taken seriously.

Over 90 percent of drugs fail to make it to market. What can the industry do to change that?

Could body-on-chip platforms eventually replace current pre-clinical animal models?

Individual plants can be viewed as living, single-use bioreactors that can be grown from seeds...

To ensure that cell therapy manufacture runs smoothly, the industry must embrace automation.

Why the pharma community should pay more attention to plants and other natural sources of new compounds.

Where would the biopharma industry be without Protein A? And can it ever be topped?